Once again, pricing concerns overshadowed all other developments in the biotech sector over the last five trading days. The NASDAQ Biotechnology Index was down a sharp 13.5% with investors remaining jittery about possible legislative action regarding escalating prices of
Biotech Stock Roundup: Pricing Concerns Hit Biotech Stocks, EU Nod for Regeneron's Praluent
